

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle

Serial No.: 09/211,297

Filed: December 14, 1998

For: Osteoprotegerin Binding Proteins

Docket No.: A-451F



Group Art Unit No.: 1646

Examiner: Draper, G.

2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. §1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner. This information disclosure statement is being filed before the mailing date of either a final Office Action under 37 C.F.R. §1.113, or a Notice of Allowance under 37 C.F.R. §1.311, whichever comes first. Payment of fees as set forth in 37 C.F.R. §1.17(p) is hereby authorized.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

12/28/2000 HVDONG1 00000069 010519 09211297

02 FC:126 180.00 CH

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: December 20, 2000

Please send all future correspondence to:
U.S. Patent Operations/ RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

December 20, 2000

Date


Signature

#7
D.Q.
1/6/01